Markets

Insider Trading

Hedge Funds

Retirement

Opinion

12 Best Healthcare Dividend Stocks To Buy Now

In this article, we discuss 12 best healthcare dividend stocks to buy now. You can skip our detailed analysis of the healthcare sector and the past performance of dividend stocks, and go directly to read 5 Best Healthcare Dividend Stocks To Buy Now

Over the span of almost four years, the COVID-19 pandemic brought about significant changes within the US healthcare system’s structure and operations. Specifically, the period between 2020 and 2021 posed substantial challenges for both payers and providers. Despite these difficulties, there was an uninterrupted momentum of innovation and expansion within healthcare services. Innovation remained a driving force, leading to the introduction of new technologies, telemedicine expansion, and novel treatment approaches. These advancements and innovations have left analysts feeling optimistic about its future prospects. Portfolio Managers at Janus Henderson Investors, Andy Acker and Dan Lyons are optimistic about this situation, suggesting it sets the stage for a promising outlook in the healthcare sector. They mentioned that healthcare is heading into the new year with lower valuations after a period of underperformance. At the same time, there’s a surge in innovation, and the effects of post-COVID adjustments are slowing down.

Don’t Miss: 20 Most Valuable Healthcare Companies in the World

The Janus Henderson report mentioned that in the biotech industry, numerous stocks are selling at larger discounts than ever before. Small and mid-sized biotech company stocks experienced significant drops in value in 2021 and 2022. This decline happened as long-term growth investments, including biotech, were affected by the increase in 10-year Treasury bond yields during 2023. The report further highlighted that the S&P Biotechnology Industry Index, which measures the performance of big biotech companies within the S&P 500 Index, is currently trading at almost a 25% lower value compared to its average over the past 30 years. Additionally, the count of early-stage biotech companies trading at a value less than the cash they hold reached an all-time high in October.

Healthcare spending in the US has historically been one of the highest among developed countries. This spending covered various aspects of healthcare, including hospital care, physician services, prescription drugs, medical equipment, and more. According to a report by The Economist, the country allocates around $4.3 trillion annually to ensure its citizens’ well-being, which represents approximately 17% of its GDP. This spending is double what other wealthy countries typically put towards healthcare. The report further mentioned that in 2022, the total earnings of the nine largest intermediaries, known as “big health,” reached about 45% of the US healthcare expenses, significantly increasing from 25% in 2013. These big health companies make up eight out of the top 25 revenue-generating firms in the S&P 500 index, while big tech comprises four, and big pharma doesn’t hold any spots among these top companies.

In 2023 so far, healthcare stocks have reported their poorest performance compared to the broader market in about 25 years. This is due to the emergence of a new group of weight-loss medications that might change the market dynamics for several profitable treatments already in existence. The S&P 500 Healthcare Index, which tracks the performance of UnitedHealth Group Incorporated (NYSE:UNH), Eli Lilly and Company (NYSE:LLY), and Merck & Co. Inc. (NYSE:MRK) is down by 3.14% year-to-date, compared with a 19.3% return of the S&P 500. In view of these arguments, we will discuss some of the best dividend stocks from the healthcare sector.

Our Methodology:

For this list, we scanned Insider Monkey’s database of Q3 2023 and picked healthcare dividend companies. From that list, we chose healthcare stocks with a strong track record of paying dividends to shareholders, which makes them resilient in the current environment. The stocks are ranked in ascending order of the hedge fund investors owning stakes in them, according to Insider Monkey’s database of Q3 2023.

12. Bristol-Myers Squibb Company (NYSE:BMY)

Number of Hedge Fund Holders: 65

Bristol-Myers Squibb Company (NYSE:BMY) is a pharmaceutical company known for its development and production of prescription drugs and biologics. The company currently pays a quarterly dividend of $0.57 per share and has a dividend yield of 4.56%, as of December 5. It is one of the best dividend stocks on our list as the company has been raising dividends consistently for the past 17 years.

At the end of Q3 2023, 65 hedge funds in Insider Monkey’s database reported having stakes in Bristol-Myers Squibb Company (NYSE:BMY), compared with 66 in the previous quarter. The collective value of these stakes is over $1.8 billion. Among these hedge funds, Two Sigma Advisors was the company’s leading stakeholder in Q3.

11. Abbott Laboratories (NYSE:ABT)

Number of Hedge Fund Holders: 69

Abbott Laboratories (NYSE:ABT) is a diversified global healthcare company that operates in several segments. The company provides solutions for healthcare professionals to diagnose and monitor various medical conditions. On September 21, the company declared a quarterly dividend of $0.51 per share, which was in line with its previous dividend. It maintains a 51-year streak of consistent dividend growth, which makes ABT one of the best dividend stocks on our list. The stock’s dividend yield on December 5 came in at 1.94%.

The number of hedge funds tracked by Insider Monkey owning stakes in Abbott Laboratories (NYSE:ABT) grew to 69 in Q3 2023, from 62 in the previous quarter. The consolidated value of these stakes is over $2.2 billion.

10. HCA Healthcare, Inc. (NYSE:HCA)

Number of Hedge Fund Holders: 71

HCA Healthcare, Inc. (NYSE:HCA) is an American leading healthcare services provider that owns and operates a vast network of hospitals across the country. The company offers a quarterly dividend of $0.60 per share and has a dividend yield of 0.93%, as of December 5.

In the third quarter of 2023, HCA Healthcare, Inc. (NYSE:HCA) reported revenue of $16.2 billion, which showed an 8.3% growth from the same period last year. The company’s operating cash flow for the quarter came in at nearly $2.5 billion. It ended the quarter with over $891 million available in cash and cash equivalents.

As of the close of Q3 2023, 71 hedge funds in Insider Monkey’s database owned stakes in HCA Healthcare, Inc. (NYSE:HCA), growing from 66 in the preceding quarter. The total value of these stakes is roughly $2 billion. With over 4.5 million shares, First Eagle Investment Management was the company’s leading stakeholder in Q3.

9. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holders: 73

Pfizer Inc. (NYSE:PFE) is an American biotech and pharmaceutical company. On October 4, the company announced a quarterly dividend of $0.41 per share, which fell in line with its previous dividend. The company raised its dividends consistently for the past 13 years, which makes PFE one of the best dividend stocks on our list. In addition to this, it also returned nearly $7 billion to shareholders through dividends during the quarter.

Pfizer Inc. (NYSE:PFE) was a part of 73 hedge fund portfolios at the end of Q3 2023, which remained unchanged from the previous quarter, as per Insider Monkey’s database. The consolidated value of these stakes is more than $2.43 billion.

8. AbbVie Inc. (NYSE:ABBV)

Number of Hedge Fund Holders: 73

AbbVie Inc. (NYSE:ABBV) is a pharmaceutical company known for its focus on developing and marketing drugs for various therapeutic areas, with a particular emphasis on immunology and oncology. The company holds a 51-year streak of consistent dividend growth, which makes ABBV one of the best dividend stocks on our list. The stock has a dividend yield of 4.30%, as of December 5.

As of the end of the third quarter of 2023, 73 hedge funds in Insider Monkey’s database owned stakes in AbbVie Inc. (NYSE:ABBV), down slightly from 74 in the preceding quarter. These stakes are collectively valued at over $3.2 billion. With nearly 4 million shares, Marshall Wace LLP was the company’s leading stakeholder in Q3.

7. The Cigna Group (NYSE:CI)

Number of Hedge Fund Holders: 74

The Cigna Group (NYSE:CI) is a global health services organization that operates in various segments within the healthcare industry. In the third quarter of 2023, the company reported revenue of $49 billion, up 8.2% from the same period last year. It posted the shareholders’ net income of $1.4 billion for the quarter or $4.74 per share.

The Cigna Group (NYSE:CI), one of the best dividend stocks on our list, currently pays a quarterly dividend of $1.23 per share. The company has raised its payouts for three consecutive years. As of December 5, the stock has a dividend yield of 1.87%.

At the end of September 2023, 74 hedge funds tracked by Insider Monkey owned investments in The Cigna Group (NYSE:CI), the same as in the previous quarter. The collective value of these stakes is over $2.84 billion.

6. Elevance Health, Inc. (NYSE:ELV)

Number of Hedge Fund Holders: 83

Previously known as Anthem, Elevance Health, Inc. (NYSE:ELV) is an Indiana-based health insurance company. The company offers a quarterly dividend of $1.48 per share and has a dividend yield of 1.23%, as of December 5. During its most recent quarter, the company distributed $348 million to shareholders through dividends, which makes ELV one of the best dividend stocks on our list.

As of the end of Q3 2023, 83 hedge funds in Insider Monkey’s database owned stakes in Elevance Health, Inc. (NYSE:ELV), up from 82 in the previous quarter. The collective value of these stakes is over $5.2 billion. Among these hedge funds, First Eagle Investment Management was the company’s leading stakeholder in Q3.

Click to continue reading and see 5 Best Healthcare Dividend Stocks To Buy Now

Suggested articles:

Disclosure. None. 12 Best Healthcare Dividend Stocks To Buy Now is originally published on Insider Monkey.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 75%.

For a ridiculously low price of just $24, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

  • The Name of the Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
  • Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
  • Lifetime Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund ANYTIME, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

  1. Head over to our website and subscribe to our Premium Readership Newsletter for just $24.
  2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
  3. Sit back, relax, and know that you’re backed by our ironclad lifetime money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…